Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections.

Doxycycline / therapeutic use HIV Infections / drug therapy Homosexuality, Male Humans Male Pre-Exposure Prophylaxis Sexual and Gender Minorities Sexually Transmitted Diseases / drug therapy
chlamydia doxycycline men who have sex with men prophylaxis syphilis

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
03 03 2020
Historique:
received: 11 05 2019
accepted: 29 08 2019
pubmed: 11 9 2019
medline: 7 1 2021
entrez: 11 9 2019
Statut: ppublish

Résumé

Bacterial sexually transmitted infections (STIs) have been increasing over the past 2 decades in gay, bisexual, and other men who have sex with men. With the widespread use of early human immunodeficiency virus (HIV) treatment, which virtually eliminates transmission risk, and the availability of HIV pre-exposure prophylaxis, there have been attitudinal changes regarding HIV infection with resultant increases in sexual contact and declines in condom use. Doxycycline is used for primary prophylaxis in a number of infectious diseases. We conducted a state-of-the-art review to examine the current state of research, knowledge gaps, and challenges around the use of doxycycline prophylaxis to prevent syphilis and other STIs. International academic and government experts met in March 2019 to frame the initial inquiry, which was supplemented by focused literature searches. Two small short-term randomized controlled trials examining doxycycline prophylaxis found high efficacy. Five additional clinical studies are underway or in development. Studies differed in design, population, outcomes, and safety measures. Doxycycline prophylaxis for bacterial STIs shows promise. Better and more robust data are needed on efficacy; target population; community acceptability; behavioral risk compensation; doxycycline dose, regimen, and formulation; long-term safety; antimicrobial resistance; cost-effectiveness; and risk-benefit.

Identifiants

DOI: 10.1093/cid/ciz866 PMID: 31504345 PMC: PMC7319058
pubmed: 31504345
pii: 5557867
doi: 10.1093/cid/ciz866
pmc: PMC7319058
doi:

Substances chimiques

Doxycycline N12000U13O

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1247-1253

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI143439
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI139265
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI028697
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Can Commun Dis Rep. 2018 Feb 01;44(2):43-48
pubmed: 29770098
Antimicrob Agents Chemother. 2010 Feb;54(2):583-9
pubmed: 19805553
AIDS Behav. 2019 Feb;23(2):548-555
pubmed: 30117076
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
Emerg Infect Dis. 2007 Mar;13(3):488-90
pubmed: 17552109
Am J Trop Med Hyg. 2011 Apr;84(4):517-31
pubmed: 21460003
Expert Opin Drug Saf. 2008 Sep;7(5):571-7
pubmed: 18759709
N Engl J Med. 1984 Feb 23;310(8):497-500
pubmed: 6363930
BMC Infect Dis. 2013 Jul 16;13:325
pubmed: 24060181
J Infect Dis. 1997 Jun;175(6):1519-22
pubmed: 9180198
N Engl J Med. 2001 Jul 12;345(2):79-84
pubmed: 11450675
Sex Transm Dis. 2018 Apr;45(4):237-242
pubmed: 29465698
J Vasc Surg. 2008 Sep;48(3):519-26; discussion 526
pubmed: 18632241
Nucleic Acids Res. 2019 Aug 22;47(14):e83
pubmed: 31114866
J Infect Dis. 2000 Apr;181(4):1421-7
pubmed: 10762573
Sex Transm Dis. 2000 Jul;27(6):343-9
pubmed: 10907910
Sex Transm Dis. 2015 Feb;42(2):104-6
pubmed: 25585070
Clin Infect Dis. 2018 Aug 16;67(5):676-686
pubmed: 29509889
BMC Infect Dis. 2013 Feb 05;13:68
pubmed: 23384348
Lancet HIV. 2018 Sep;5(9):e482
pubmed: 30215346
N Engl J Med. 2004 Jul 8;351(2):154-8
pubmed: 15247355
Science. 1998 Jul 17;281(5375):375-88
pubmed: 9665876
Sex Transm Dis. 2011 Jul;38(7):573-9
pubmed: 21343845
Curr Clin Microbiol Rep. 2016;3:10-18
pubmed: 27218014
J Vasc Surg. 2001 Oct;34(4):606-10
pubmed: 11668312
J Vasc Surg. 2002 Jul;36(1):1-12
pubmed: 12096249
Sex Transm Dis. 2015 Feb;42(2):98-103
pubmed: 25585069
J Antimicrob Chemother. 2018 Mar 1;73(3):680-686
pubmed: 29207004
Malar J. 2015 Nov 10;14:445
pubmed: 26555664
Sex Transm Dis. 2019 Apr;46(4):e32-e34
pubmed: 30870327
Sex Transm Infect. 2018 Feb;94(1):9-13
pubmed: 28717051
J Infect Dis. 1982 Dec;146(6):811-8
pubmed: 6815282
Sex Transm Dis. 2016 May;43(5):310-6
pubmed: 27100768
AIDS. 2018 Feb 20;32(4):523-530
pubmed: 29239887
J Clin Epidemiol. 2016 Aug;76:89-98
pubmed: 26931285
Antimicrob Agents Chemother. 1988 Jan;32(1):68-74
pubmed: 2964810
Lancet Infect Dis. 2018 Mar;18(3):308-317
pubmed: 29229440
Ann Intern Med. 2013 Dec 17;159(12):815-23
pubmed: 24490266
J Antimicrob Chemother. 2018 Mar 1;73(3):553-563
pubmed: 29182717
JAMA. 2019 Apr 9;321(14):1380-1390
pubmed: 30964528

Auteurs

Juliana S Grant (JS)

JSG Health, LLC, Seattle, Washington DC, USA.

Chrysovalantis Stafylis (C)

Division of Infectious Diseases, University of California-Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, USA.

Connie Celum (C)

Department of Global Health, University of Washington, Seattle, Washington DC, USA.
Department of Medicine, University of Washington, Seattle, Washington DC, USA.
Department of Epidemiology, University of Washington, Seattle, Washington DC, USA.

Troy Grennan (T)

British Columbia Centre for Disease Control and Division of Infectious Diseases, University of British Columbia, Vancouver, Canada.

Bridget Haire (B)

The Kirby Institute, University of New South Wales, Sydney, Australia.

John Kaldor (J)

The Kirby Institute, University of New South Wales, Sydney, Australia.

Anne F Luetkemeyer (AF)

Zuckerberg San Francisco General, University of California, San Francisco, California, USA.

John M Saunders (JM)

Blood Safety, Hepatitis, STI, and HIV Division, National Infection Service, Public Health England, London, United Kingdom.

Jean-Michel Molina (JM)

Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France.
INSERM U944, Paris, France.

Jeffrey D Klausner (JD)

Division of Infectious Diseases, University of California-Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, USA.
Department of Epidemiology, University of California-Los Angeles (UCLA), Los Angeles, California, USA.
Fielding School of Public Health, University of California-Los Angeles (UCLA), Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Naphtacènes › Tétracyclines › Doxycycline › Doxycycline Prophylaxis for Bacterial Sexually...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Doxycycline Prophylaxis for Bacterial Sexually...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Sexualité › Homosexualité › Homosexualité masculine › Doxycycline Prophylaxis for Bacterial Sexually...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Doxycycline Prophylaxis for Bacterial Sexually...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Prophylaxie pré-exposition › Doxycycline Prophylaxis for Bacterial Sexually...
questionsmedicales.fr › Personnes › Disparités en matière de santé, minorités et populations vulnérables › Minorités sexuelles › Doxycycline Prophylaxis for Bacterial Sexually...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies sexuellement transmissibles › Doxycycline Prophylaxis for Bacterial Sexually...